Abstract 285P
Background
Reticulocyte hemoglobin equivalent (RET-He) measures the amount of hemoglobin in the reticulocytes and indicates red cell hemoglobinization, reflecting the quality of the newly produced reticulocytes. It is a useful parameter which allows the diagnosis of IDA before it manifests clinically in a patient and also for treatment follow-up. Therefore, the ability to assess iron deficiency, as part of automated CBC/reticulocyte analysis, may significantly enhance patient management. Etiology of CRA is multifactorial, and is due to myelosuppression secondary to chemotherapy, bone marrow failure, chronic inflammation, and/or iron deficiency. The goal of the present study was to establish a RET-He cut-off that could rapidly predict iron deficiency. The data suggests that RET-He, at a threshold of 32 pg/ cell, may be an important discriminator to rule out IDA in patients with cancer.
Methods
Patients were enrolled into the study based on the laboratory test values of CBC and serum iron studies.
Results
The statistical analysis was performed using (A) biochemical standards for ID i.e. serum iron less than 40 μg/dL, transferrin saturation less than 20% as well as (B) our in house standards i.e serum iron less than 40 μg/dL, transferrin saturation less than 30% with a RET-He cut-off at 30.4 pg. The PPV was calculated at 70.67 % and 75.9% for A & B respectively. The results were statistically significant in both (A) and (B) i.e. P value <0.001 as per table. Table: 285P
RET-He Cut-off <30.4 pg | TSAT <20%, serum Iron <40 μg/dL (Protocol Values) (A) | TSAT <30%, serum Iron <40 μg/dL(In house values)(B) |
Sensitivity % | 67.4 | 67.8 |
Specificity % | 64.5 | 68 |
Negative Predictive Value (NPV)% | 61.2 | 58.6 |
Positive Predictive Value (PPV)% | 70.67 | 75.9 |
Conclusions
RET-He is a readily available parameter on automated hematology analyzers with no additional cost and effort. Hence, we recommend the incorporation of RET-He in the diagnostic algorithm for the rapid assessment of IDA in the oncology practice as a surrogate marker with cut-off value <30.4 pg which had a PPV of 76%.This will negate the requirement of iron biochemistry studies in CRA patients, expedite the process of anemia correction with I.v. iron therapy and further reduce the requirement of additional blood sampling, along with providing cost efficacy to the patient especially in the cost-limited healthcare settings. In case of non-responders, a further extensive work up should be performed to delineate the etiology of CRA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
281P - Cancer-related symptoms as mediators between treatment and functional capacity in adolescents and young adults (AYAs) with cancer
Presenter: Chung Tin Justin Ma
Session: Poster viewing 04
282P - Nutritional status and nutritional therapy of common cancer in a cancer hospital of Southwest China
Presenter: Huiqing Yu
Session: Poster viewing 04
283P - Comparative analysis of osteoporotic fracture (OF) and pathologic fracture (PF) in patients with metastatic colorectal cancer (mCRC) who received palliative chemotherapy
Presenter: Yejee Lim
Session: Poster viewing 04
284P - Gut microbiota mediates the protective effects of resveratrol against the intestinal barrier dysfunction in non-alcoholic steatohepatitis induced by high-fat diet
Presenter: Haoyang Cao
Session: Poster viewing 04
286P - Breakthrough COVID-19 infections in patients with cancer from a prospective study of COVID-19 vaccine response
Presenter: Amy Body
Session: Poster viewing 04
287P - Long-term yoga enhances the quality of life and symptomatic scale in breast cancer patients undergoing treatment
Presenter: Mayank Jain
Session: Poster viewing 04
288P - Impact of hormonal contraception on estradiol and progesterone serum levels: A 6-year study on progression-free survival, disease-free survival, and overall survival at Dr. Moewardi Hospital
Presenter: Widyanti Soewoto
Session: Poster viewing 04
289P - Cancer cachexia following breast cancer (BC) chemotherapy was associated with clinical stage, number of chemotherapy cycles, and vitamin D concentration
Presenter: Susanna Hutajulu
Session: Poster viewing 04
290P - Use of PEG G-CSF is associated with decreased myelotoxicity in dexrazoxane-used aggressive non-Hodgkin lymphoma patients
Presenter: Sung-Nam Lim
Session: Poster viewing 04
291P - Assessment of nutritional status in cancer patients using patient generated subjective global assessment screening tool
Presenter: Anuj K. C.
Session: Poster viewing 04